Baudax Bio is a specialty pharmaceutical company focused on developing and commercializing innovative products for acute care settings.
We currently have multiple therapeutic candidates across early, mid and late-stage clinical development, including one candidate in later stage regulatory review with FDA.
Our product pipeline contains valuable therapeutic product candidate options for patients and healthcare providers in acute care settings.
Baudax Bio Announces Closing of $25 Million Public Offering of Securities
Baudax Bio Announces Pricing of Public Offering of Common Stock and Warrants
Baudax Bio Announces Proposed Public Offering of Common Stock and Warrants
Baudax Bio Signs Non-Binding Term Sheet for Debt Facility
Baudax Bio Announces FDA Approval of ANJESO™ for the Management of Moderate to Severe Pain
Baudax Bio Reports 2019 Annual Financial Results
Baudax Bio Announces PDUFA Date for Intravenous Meloxicam
Baudax Bio to Present at the Piper Jaffray 31st Annual Healthcare Conference
Baudax Bio™ Launches as a New Pharmaceutical Company Aimed at Advancing Promising, Non-Opioid Analgesic Therapies
Stay informed and receive company updates straight to your inbox.